Thomas H. Lee Partners Acquires Intelligent Medical Objects
Investment will support expanded product development and go-to-market activities
ROSEMONT, Ill. & BOSTON–(BUSINESS WIRE)–Thomas H. Lee Partners, L.P. (“THL”), a premier private equity firm investing in growth companies, announced today that it has entered into an agreement to acquire a majority interest in Intelligent Medical Objects (“IMO,” or “the Company”), a healthcare data enablement company and market leader in clinical terminology solutions from Warburg Pincus, a leading global growth investor. THL’s investment will support the Company’s product development and expanded commercial relationships with hospitals and other health care providers.
Founded in 1994, IMO manages more than 5 million clinical terms and maps to all major coding systems. Its suite of software products, which is used by over 740,000 physicians daily, helps hospitals minimize clinician burnout, reduce unnecessary care and charges, optimize billing and reimbursement, streamline data management, and inform better care. The Company’s newer offerings help improve data quality by streamlining clinical workflows and standardizing patient condition and treatment data.
“We could not be more excited to partner with our new colleagues at IMO,” said Joshua Nelson, Managing Director at THL and Head of the firm’s Healthcare group. “At a time when hospitals and physicians feel the strain of heightened demand and limited capacity, IMO’s products help deliver improved patient care and satisfaction. This works to the benefit of those providing care, and those seeking it.”
“THL’s investment in IMO validates the next stage of growth for our business, our products, and our employees,” said Ann Barnes, IMO’s CEO. “For three decades, IMO has been building products critical to addressing healthcare’s most pressing health IT needs and this partnership allows us to accelerate our expansion in both provider and non-provider markets.”
“IMO has built sophisticated products that eliminate many of the legacy inefficiencies and asymmetries in medical billing, scheduling, and clinical record keeping,” said Shahab Vagefi, Managing Director at THL. “We see a blue-sky opportunity to build on these products and expand the Company’s relationships with hospitals and health care providers nationwide.”
“We are incredibly proud of IMO’s tremendous growth over the past six years of our partnership. Through the launch of innovative products, expansion into new markets and the support of strong talent at the Company, IMO remains a leader in simplifying complex healthcare data for thousands of hospitals and physicians,” said Vishnu Menon, Managing Director, Warburg Pincus and Andrew Park, Managing Director, Warburg Pincus. “IMO is well positioned for continued success, and we look forward to the next chapter of its growth,” added Parag Gupta, Managing Director, Warburg Pincus.
Evercore acted as the exclusive financial advisor and Kirkland & Ellis acted as legal advisor to IMO. William Blair acted as financial advisor, Ropes & Gray acted as legal advisor, Kirkland & Ellis acted as financing legal advisor and Deloitte acted as accounting and tax advisor to THL.
About Thomas H. Lee Partners
Thomas H. Lee Partners, L.P. (“THL”) is a premier private equity firm investing in middle-market growth companies exclusively in three sectors: Healthcare, Financial Technology and Services, and Technology & Business Solutions. THL couples deep sector expertise through our Identified Sector Opportunity (“ISO”) process with dedicated internal operating resources from our Strategic Resource Group (“SRG”) to transform and build great companies of lasting value in partnership with management. The Firm’s domain expertise and resources help to build great companies with an aim to accelerate growth, improve operations and drive long-term sustainable value. Since 1974, THL has raised more than $30 billion of equity capital, invested in over 160 companies and completed more than 500 add-on acquisitions representing an aggregate enterprise value at acquisition of over $210 billion.
Intelligent Medical Objects (IMO) is a healthcare data enablement company. From clinical documentation at the point of care to complex approaches to population health management, IMO ensures clinical data integrity and quality—making patient information fit-for-purpose across the healthcare ecosystem. For almost three decades, IMO’s footprint in EHRs—across more than 4,500 US hospitals—powers our expert ability to capture and preserve clinical intent wherever and however data is used. Our primary clients span individual doctors and physician groups, hospitals and clinics, large integrated delivery networks, inpatient ORs and surgical centers, global electronic health record providers, health information exchanges, clinical data registries, payers, life sciences companies, and healthcare analytics vendors. For more information visit: IMOHEALTH.COM.
About Warburg Pincus
Warburg Pincus LLC is a leading global growth investor. The firm has more than $73 billion in assets under management. The firm’s active portfolio of more than 235 companies is highly diversified by stage, sector, and geography. Warburg Pincus is an experienced partner to management teams seeking to build durable companies with sustainable value. Since inception, the firm has invested over $12 billion in more than 160 healthcare companies and over $25 billion in more than 360 technology companies. The intersection of these two sectors in HCIT is a key area of focus for the firm, with current investments including Aetion, Experity, Global Healthcare Exchange (GHX), Helix, Modernizing Medicine, Phil, Qualifacts, Quantum Health, and WebPT. Founded in 1966, Warburg Pincus has raised 20 private equity and 2 real estate funds, which have invested more than $100 billion in over 1,000 companies in more than 40 countries. The firm is headquartered in New York with offices in Amsterdam, Beijing, Berlin, Hong Kong, Houston, London, Luxembourg, Mumbai, Mauritius, San Francisco, São Paulo, Shanghai, and Singapore.